{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:53:37Z","timestamp":1791078817568,"version":"4.1.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This update addresses HIV\/TB co-infection management in pregnancy, focusing on new treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Pregnancy with HIV increases TB risk and worsens treatment outcomes. While long-acting antiretroviral therapies (LA-ART) like cabotegravir\/rilpivirine and lenacapavir exist, data on their safety and efficacy in pregnant individuals are limited. Treating both HIV and TB is crucial, but pregnancy\u2019s physiological changes complicate drug management. Standard ART and TB preventive therapy (TPT) with isoniazid are recommended after excluding active TB, despite some concerns about adverse outcomes when combined with ARV treatment. For active drug-resistant TB, the new 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) is not recommended in pregnancy due to limited safety data on pretomanid. Instead, a 9-month regimen is preferred, though bedaquiline and pretomanid are likely safe. More research on these new therapies in pregnant populations is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>While standard ART remains the recommended approach for HIV\/TB co-infection in pregnancy, further research is crucial to establish the safety and efficacy of newer LA-ART and bedaquiline-based TB regimens in this high-risk population. Concerns around the safety of TPT in pregnancy remain unanswered and further prospective research is urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11904-025-00746-z","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T23:50:53Z","timestamp":1750031453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Update on the Clinical Management of HIV and Tuberculosis Co-Infection in Pregnancy: TB Preventative Therapy, Long-Acting ARVs, and Bedaquiline-Based Regimens"],"prefix":"10.1007","volume":"22","author":[{"given":"Tim","family":"Crocker-Buque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Moso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Denholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasha P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"746_CR1","volume-title":"Global tuberculosis report 2022","author":"WHO","year":"2022","unstructured":"WHO. Global tuberculosis report 2022. Geneva, Switzerland: Pub. World Health Organization; 2022."},{"key":"746_CR2","volume-title":"Global tuberculosis report 2024","author":"WHO","year":"2024","unstructured":"WHO. Global tuberculosis report 2024. Geneva, Switzerland: Pub. World Health Organisation; 2024."},{"key":"746_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cid\/ciw778","volume":"64","author":"DM Lewinsohn","year":"2017","unstructured":"Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American thoracic society\/infectious diseases society of america\/centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64:111\u20135.","journal-title":"Clin Infect Dis"},{"key":"746_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00126334-200001010-00010","volume":"23","author":"R Wood","year":"2000","unstructured":"Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000;23:75\u201380.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"746_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1086\/426827","volume":"191","author":"P Sonnenberg","year":"2005","unstructured":"Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191:150\u20138.","journal-title":"J Infect Dis"},{"key":"746_CR6","first-page":"CD000171","volume":"2010","author":"C Akolo","year":"2010","unstructured":"Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;2010:CD000171.","journal-title":"Cochrane Database Syst Rev"},{"key":"746_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1164\/rccm.201106-1083OC","volume":"185","author":"D Zenner","year":"2012","unstructured":"Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy. Am J Respir Crit Care Med. 2012;185:779\u201384.","journal-title":"Am J Respir Crit Care Med"},{"key":"746_CR8","doi-asserted-by":"publisher","first-page":"e0003578","DOI":"10.1371\/journal.pgph.0003578","volume":"4","author":"AJ Morton","year":"2024","unstructured":"Morton AJ, Mitchell AR, Melville RE, Hui L, Tong SYC, Dunstan SJ, et al. Mycobacterium tuberculosis infection in pregnancy: A systematic review. PLOS Global Public Health. 2024;4:e0003578.","journal-title":"PLOS Global Public Health"},{"key":"746_CR9","unstructured":"WHO. TB and pregnancy. 2024. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024\/featured-topics\/tb-and-pregnancy (accessed January 15, 2025)."},{"key":"746_CR10","doi-asserted-by":"publisher","first-page":"e081209","DOI":"10.1136\/bmjopen-2023-081209","volume":"14","author":"S-A Meehan","year":"2024","unstructured":"Meehan S-A, Hesseling AC, von Delft A, Marx FM, Hughes JA, Bock P, et al. Association between tuberculosis and pregnancy outcomes: a retrospective cohort study of women in cape town, South Africa. BMJ Open. 2024;14:e081209.","journal-title":"BMJ Open"},{"key":"746_CR11","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.cegh.2020.05.003","volume":"8","author":"A Yaghoubi","year":"2020","unstructured":"Yaghoubi A, Salehabadi S, Abdeahad H, Hasanian SM, Avan A, Yousefi M, et al. Tuberculosis, human immunodeficiency viruses and TB\/HIV co-infection in pregnant women: A meta-analysis. Clin Epidemiol Global Health. 2020;8:1312\u201320.","journal-title":"Clin Epidemiol Global Health"},{"key":"746_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0020-7292(94)90064-7","volume":"44","author":"N Jana","year":"1994","unstructured":"Jana N, Vasishta K, Jindal SK, Khunnu B, Ghosh K. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. Int J Gynaecol Obstet. 1994;44:119\u201324.","journal-title":"Int J Gynaecol Obstet"},{"key":"746_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199908263410903","volume":"341","author":"N Jana","year":"1999","unstructured":"Jana N, Vasishta K, Saha SC, Ghosh K. Obstetrical outcomes among women with extrapulmonary tuberculosis. N Engl J Med. 1999;341:645\u20139.","journal-title":"N Engl J Med"},{"key":"746_CR14","doi-asserted-by":"crossref","unstructured":"Khan M, Pillay T, Moodley JM, Connolly CA, Durban Perinatal, TB HIV-1 Study Group. Maternal mortality associated with tuberculosis-HIV-1 co-infection in durban, South Africa. AIDS. 2001;15:1857\u201363.","DOI":"10.1097\/00002030-200109280-00016"},{"key":"746_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1473-3099(04)00939-9","volume":"4","author":"T Pillay","year":"2004","unstructured":"Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H. Perinatal tuberculosis and HIV-1: considerations for resource-limited settings. Lancet Infect Dis. 2004;4:155\u201365.","journal-title":"Lancet Infect Dis"},{"key":"746_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/518974","volume":"45","author":"A Gupta","year":"2007","unstructured":"Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in pune, india, 2002\u20132005. Clin Infect Dis. 2007;45:241\u20139.","journal-title":"Clin Infect Dis"},{"key":"746_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/cix851","volume":"66","author":"N Salazar-Austin","year":"2018","unstructured":"Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency Virus-Infected pregnant women with tuberculosis in South africa: the Tshepiso study. Clin Infect Dis. 2018;66:921\u20139.","journal-title":"Clin Infect Dis"},{"key":"746_CR18","doi-asserted-by":"publisher","first-page":"1239734","DOI":"10.3389\/fpubh.2023.1239734","volume":"11","author":"HS Schaaf","year":"2023","unstructured":"Schaaf HS, Bekker A, Rabie H. Perinatal tuberculosis-An approach to an under-recognized diagnosis. Front Public Health. 2023;11:1239734.","journal-title":"Front Public Health"},{"key":"746_CR19","unstructured":"Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States 2024. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal\/whats-new (accessed January 15, 2025)."},{"key":"746_CR20","unstructured":"EACS. EACS Guidelines 2024. European AIDS clinical society guidelines. Available from: https:\/\/eacs.sanfordguide.com (accessed May 22, 2025)."},{"key":"746_CR21","unstructured":"BHIVA. BHIVA guidelines on the management of HIV in pregnancy and the postpartum period 2024. Available from: https:\/\/bhiva.org\/pregnancy-guidelines-consultation, (accessed May 22, 2025)."},{"key":"746_CR22","unstructured":"Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry interim report for 1 January 1989 through 31 January 2024. Available from: https:\/\/www.apregistry.com\/ (accessed January 15, 2025)."},{"key":"746_CR23","doi-asserted-by":"crossref","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, G\u00fcnthard HF et al. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society\u2013USA Panel. JAMA. 2025;333(7):609\u201328.","DOI":"10.1001\/jama.2024.24543"},{"key":"746_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1128\/AAC.00370-11","volume":"56","author":"S Benaboud","year":"2012","unstructured":"Benaboud S, Tr\u00e9luyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother. 2012;56:776\u201382.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","volume":"32","author":"N Mulligan","year":"2018","unstructured":"Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32:729\u201337.","journal-title":"AIDS"},{"key":"746_CR26","doi-asserted-by":"publisher","first-page":"ofae672","DOI":"10.1093\/ofid\/ofae672","volume":"11","author":"C Brites","year":"2024","unstructured":"Brites C, Luz E, N\u00f3brega I, Luz I, Zajdenverg R, de Ruiter A, et al. Efficacy and safety of DTG\/3TC for prophylaxis of HIV perinatal transmission: A pilot study (PREGNANCY). Open Forum Infect Dis. 2024;11:ofae672.","journal-title":"Open Forum Infect Dis"},{"key":"746_CR27","unstructured":"Pagnucco L, Bruno R, Zuccaro V. Could dolutegravir\/lamivudine be a valid dual-therapy option even in pregnancy? Data from a retrospective analysis. J Int AIDS Soc Conf Abs. 2022;P005."},{"key":"746_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/hiv.13370","volume":"24","author":"R D\u2019Amico","year":"2023","unstructured":"D\u2019Amico R, Cenoz Gomis S, Moodley R, Van Solingen-Ristea R, Baugh B, Van Landuyt E, et al. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy. HIV Med. 2023;24:202\u201311.","journal-title":"HIV Med"},{"key":"746_CR29","doi-asserted-by":"crossref","unstructured":"Hickey MD, Gistand N, Grochowski J, Mayorga-Munoz F, Imbert E, Szumowski JD et al. 48-week viral suppression rates in people with HIV starting long-acting CAB\/RPV with initial viremia. Clin Infect Dis 2024;ciae500.","DOI":"10.1093\/cid\/ciae500"},{"key":"746_CR30","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/cid\/cix534","volume":"65","author":"S Schalkwijk","year":"2017","unstructured":"Schalkwijk S, Colbers A, Konopnicki D, Gingelmaier A, Lambert J, van der Ende M, et al. Lowered rilpivirine exposure during the third trimester of pregnancy in human immunodeficiency virus type 1-Infected women. Clin Infect Dis. 2017;65:1335\u201341.","journal-title":"Clin Infect Dis"},{"key":"746_CR31","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/cid\/ciae242","volume":"79","author":"L van der Wekken-Pas","year":"2024","unstructured":"van der Wekken-Pas L, Weiss F, Simon-Zuber C, Sebisch R, Wiese C, van Leeuwen E, et al. Long-Acting injectable cabotegravir and rilpivirine in a pregnant woman with HIV. Clin Infect Dis. 2024;79:1468\u201371.","journal-title":"Clin Infect Dis"},{"key":"746_CR32","doi-asserted-by":"crossref","unstructured":"Atoyebi S, Bunglawala F, Cottura N, Gra\u00f1ana-Castillo S, Montanha MC, Olagunju A et al. Physiologically-based Pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. Br J Clin Pharmacol. 2024;91(4):989\u20131002. https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16006","DOI":"10.1111\/bcp.16006"},{"key":"746_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/COH.0000000000000735","volume":"17","author":"C Flexner","year":"2022","unstructured":"Flexner C. The future of long-acting agents for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17:192\u20138.","journal-title":"Curr Opin HIV AIDS"},{"key":"746_CR34","unstructured":"Marzinke M, Voldal E, Hasncom B. Evaluation of long-acting cabotegravir (CAB-LA) pharmacokinetics during pregnancy: a sub-study analysis of the HPTN 084 open label extension study. Abstract SY2504, International Aids Society; 2024."},{"key":"746_CR35","unstructured":"Delany-Moretlwe S, Voldal E, Saldi F. Initial evaluation of injectable cabotegravir (CAB-LA) safety during pregnancy in the HPTN 084 open-label extension. Abstract SY2503. 2024."},{"key":"746_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/COH.0000000000000733","volume":"17","author":"MA Spinelli","year":"2022","unstructured":"Spinelli MA, Grinsztejn B, Landovitz RJ. Promises and challenges: cabotegravir for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17:186\u201391.","journal-title":"Curr Opin HIV AIDS"},{"key":"746_CR37","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"L-G Bekker","year":"2024","unstructured":"Bekker L-G, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-Yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391:1179\u201392.","journal-title":"N Engl J Med"},{"key":"746_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/QAI.0000000000000668","volume":"70","author":"A Stek","year":"2015","unstructured":"Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, et al. Pharmacokinetics of once versus twice daily Darunavir in pregnant HIV-Infected women. J Acquir Immune Defic Syndr. 2015;70:33\u201341.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"746_CR39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/hiv.12721","volume":"20","author":"HM Crauwels","year":"2019","unstructured":"Crauwels HM, Osiyemi O, Zorrilla C, Bicer C, Brown K. Reduced exposure to Darunavir and cobicistat in HIV-1-infected pregnant women receiving a Darunavir\/cobicistat-based regimen. HIV Med. 2019;20:337\u201343.","journal-title":"HIV Med"},{"key":"746_CR40","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-024-01445-1","volume":"47","author":"J Shafi","year":"2024","unstructured":"Shafi J, Virk MK, Kalk E, Carlucci JG, Chepkemoi A, Bernard C, et al. Pharmacovigilance in pregnancy studies, exposures and outcomes ascertainment, and findings from Low- and Middle-Income countries: A scoping review. Drug Saf. 2024;47:957\u201390.","journal-title":"Drug Saf"},{"key":"746_CR41","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/ejcn.2014.40","volume":"68","author":"EM Widen","year":"2014","unstructured":"Widen EM, Gallagher D. Body composition changes in pregnancy: measurement, predictors and outcomes. Eur J Clin Nutr. 2014;68:643\u201352.","journal-title":"Eur J Clin Nutr"},{"key":"746_CR42","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/cpt.2192","volume":"109","author":"P Hazenberg","year":"2021","unstructured":"Hazenberg P, Navaratnam K, Busuulwa P, Waitt C. Anti-Infective dosing in special populations: pregnancy. Clin Pharmacol Ther. 2021;109:977\u201386.","journal-title":"Clin Pharmacol Ther"},{"key":"746_CR43","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1515\/jbcpp-2021-0312","volume":"33","author":"AC Eke","year":"2022","unstructured":"Eke AC. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. J Basic Clin Physiol Pharmacol. 2022;33:581\u201398.","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"746_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00003088-197702030-00002","volume":"2","author":"B Krauer","year":"1977","unstructured":"Krauer B, Krauer F. Drug kinetics in pregnancy. Clin Pharmacokinet. 1977;2:167\u201381.","journal-title":"Clin Pharmacokinet"},{"key":"746_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11904-022-00641-x","volume":"19","author":"AJ Jones","year":"2022","unstructured":"Jones AJ, Mathad JS, Dooley KE, Eke AC. Evidence for implementation: management of TB in HIV and pregnancy. Curr HIV\/AIDS Rep. 2022;19:455\u201370.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"746_CR46","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1128\/AAC.02051-15","volume":"60","author":"P Denti","year":"2016","unstructured":"Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, et al. Population pharmacokinetics of Rifampin in pregnant women with tuberculosis and HIV coinfection in soweto, South Africa. Antimicrob Agents Chemother. 2016;60:1234\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR47","doi-asserted-by":"publisher","unstructured":"Abdelwahab MT, Leisegang R, Dooley KE, Mathad JS, Wiesner L, McIlleron H, et al. Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant South African women with tuberculosis and HIV. Antimicrob Agents Chemother. 2020;64. https:\/\/doi.org\/10.1128\/aac.01978-19.","DOI":"10.1128\/aac.01978-19"},{"key":"746_CR48","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa1813060","volume":"381","author":"A Gupta","year":"2019","unstructured":"Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-Infected pregnant and postpartum women. N Engl J Med. 2019;381:1333\u201346.","journal-title":"N Engl J Med"},{"key":"746_CR49","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/cpt.2044","volume":"109","author":"K Gausi","year":"2021","unstructured":"Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, et al. Pharmacokinetics and Drug-Drug interactions of Isoniazid and Efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping. Clin Pharmacol Ther. 2021;109:1034\u201344.","journal-title":"Clin Pharmacol Ther"},{"key":"746_CR50","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/cid\/ciab665","volume":"74","author":"JS Mathad","year":"2022","unstructured":"Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, et al. Pharmacokinetics and safety of 3 months of weekly rifapentine and Isoniazid for tuberculosis prevention in pregnant women. Clin Infect Dis. 2022;74:1604\u201313.","journal-title":"Clin Infect Dis"},{"key":"746_CR51","first-page":"151","volume":"104","author":"AL Franks","year":"1989","unstructured":"Franks AL, Binkin NJ, Snider DE, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104:151\u20135.","journal-title":"Public Health Rep"},{"key":"746_CR52","doi-asserted-by":"crossref","unstructured":"Hamada Y, Figueroa C, Mart\u00edn-S\u00e1nchez M, Falzon D, Kanchar A. The safety of Isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis. Eur Respir J. 2020;55.","DOI":"10.1183\/13993003.01967-2019"},{"key":"746_CR53","doi-asserted-by":"publisher","first-page":"506","DOI":"10.5588\/ijtld.23.0078","volume":"27","author":"KP Singh","year":"2023","unstructured":"Singh KP, Carvalho ACC, Centis R, D\u00b4Ambrosio L, Migliori GB, Mpagama SG, et al. Clinical standards for the management of adverse effects during treatment for TB. Int J Tuberc Lung Dis. 2023;27:506\u201319.","journal-title":"Int J Tuberc Lung Dis"},{"key":"746_CR54","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/thx.2006.058867","volume":"61","author":"Ra Breen","year":"2006","unstructured":"Breen Ra, Miller M, Gorsuch RF, Smith T, Schwenk CJ, Holmes A. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61:791\u20134.","journal-title":"Thorax"},{"key":"746_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1258\/ijsa.2008.008361","volume":"20","author":"DJB Marks","year":"2009","unstructured":"Marks DJB, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS. 2009;20:339\u201345.","journal-title":"Int J STD AIDS"},{"key":"746_CR56","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/cid\/ciu094","volume":"58","author":"H Masur","year":"2014","unstructured":"Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE, et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the centers for disease control and prevention, National institutes of health, and HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014;58:1308\u201311.","journal-title":"Clin Infect Dis"},{"key":"746_CR57","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"WHO","year":"2018","unstructured":"WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Pub: World Health Organization, Geneva, Switzerland;; 2018."},{"key":"746_CR58","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5588\/ijtld.21.0753","volume":"26","author":"GB Migliori","year":"2022","unstructured":"Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S, et al. Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis. 2022;26:190\u2013205.","journal-title":"Int J Tuberc Lung Dis"},{"key":"746_CR59","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839\u201354.","journal-title":"Drugs"},{"key":"746_CR60","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","volume":"40","author":"WJ Burman","year":"2001","unstructured":"Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327\u201341.","journal-title":"Clin Pharmacokinet"},{"key":"746_CR61","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dky152","volume":"73","author":"KE Stott","year":"2018","unstructured":"Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73:2305\u201313.","journal-title":"J Antimicrob Chemother"},{"key":"746_CR62","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","volume":"58","author":"AA Abulfathi","year":"2019","unstructured":"Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet. 2019;58:1103\u201329.","journal-title":"Clin Pharmacokinet"},{"key":"746_CR63","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","volume":"50","author":"H McIlleron","year":"2006","unstructured":"McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50:1170\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR64","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/106002809603000901","volume":"30","author":"CA Peloquin","year":"1996","unstructured":"Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996;30:919\u201325.","journal-title":"Ann Pharmacother"},{"key":"746_CR65","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1086\/599040","volume":"48","author":"S Chideya","year":"2009","unstructured":"Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin, ethambutol, and Pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-Infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48:1685\u201394.","journal-title":"Clin Infect Dis"},{"key":"746_CR66","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5588\/ijtld.23.0031","volume":"27","author":"C Maugans","year":"2023","unstructured":"Maugans C, Loveday M, Hlangu S, Waitt C, Van Schalkwyk M, van de Water B, et al. Best practices for the care of pregnant people living with TB. Int J Tuberc Lung Dis. 2023;27:357\u201366.","journal-title":"Int J Tuberc Lung Dis"},{"key":"746_CR67","doi-asserted-by":"crossref","first-page":"e00737","DOI":"10.1128\/aac.00737-23","volume":"67","author":"M Van Schalkwyk","year":"2023","unstructured":"Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, Cotton MF, et al. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and Pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023;67:e00737\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR68","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","volume":"62","author":"KE Dooley","year":"2013","unstructured":"Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with Rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"746_CR69","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3018(23)00081-4","volume":"10","author":"R Griesel","year":"2023","unstructured":"Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene CM, et al. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. Lancet HIV. 2023;10:e433\u201341.","journal-title":"Lancet HIV"},{"key":"746_CR70","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jama.300.5.530","volume":"300","author":"A Boulle","year":"2008","unstructured":"Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530\u20139.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"746_CR71","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","volume":"22","author":"TF Blaschke","year":"1996","unstructured":"Blaschke TF, Skinner MH. The clinical pharmacokinetics of Rifabutin. Clin Infect Dis. 1996;22(Suppl 1):S15\u201322.","journal-title":"Clin Infect Dis"},{"key":"746_CR72","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1128\/AAC.01749-09","volume":"54","author":"V Sekar","year":"2010","unstructured":"Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, et al. Pharmacokinetics of darunavir\/ritonavir and Rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54:4440\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR73","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1067\/mcp.2003.3","volume":"73","author":"FM Hamzeh","year":"2003","unstructured":"Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, et al. Steady-state Pharmacokinetic interaction of modified-dose indinavir and Rifabutin. Clin Pharmacol Ther. 2003;73:159\u201369.","journal-title":"Clin Pharmacol Ther"},{"key":"746_CR74","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/j.clinthera.2020.09.009","volume":"42","author":"B-L Hong","year":"2020","unstructured":"Hong B-L, D\u2019Cunha R, Li P, Al-Shaer MH, Alghamdi WA, An G, et al. A systematic review and Meta-analysis of Isoniazid pharmacokinetics in healthy volunteers and patients with tuberculosis. Clin Ther. 2020;42:e220\u201341.","journal-title":"Clin Ther"},{"key":"746_CR75","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1086\/431984","volume":"41","author":"JW Tappero","year":"2005","unstructured":"Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005;41:461\u20139.","journal-title":"Clin Infect Dis"},{"key":"746_CR76","doi-asserted-by":"publisher","first-page":"e0141002","DOI":"10.1371\/journal.pone.0141002","volume":"10","author":"P Denti","year":"2015","unstructured":"Denti P, Jeremiah K, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N, et al. Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania. PLoS ONE. 2015;10:e0141002.","journal-title":"PLoS ONE"},{"key":"746_CR77","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.tube.2019.04.012","volume":"116","author":"ER Erwin","year":"2019","unstructured":"Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: the good, the bad, and the alternatives. Tuberculosis. 2019;116:S66\u201370.","journal-title":"Tuberculosis"},{"key":"746_CR78","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/cts.13614","volume":"16","author":"OU Amaeze","year":"2023","unstructured":"Amaeze OU, Isoherranen N. Application of a physiologically based Pharmacokinetic model to predict Isoniazid disposition during pregnancy. Clin Transl Sci. 2023;16:2163\u201376.","journal-title":"Clin Transl Sci"},{"key":"746_CR79","first-page":"1360","volume":"8","author":"M Zhu","year":"2004","unstructured":"Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis. 2004;8:1360\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"746_CR80","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1128\/AAC.00274-11","volume":"55","author":"S J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson S, Davidse A, Wilkins J, Van der Walt J-S, Simonsson USH, Karlsson MO, et al. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother. 2011;55:4230\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR81","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/pathogens12121385","volume":"12","author":"J Hughes","year":"2023","unstructured":"Hughes J. Pharmacokinetics and safety of group A and B Anti-Tuberculosis drugs used in treatment of Rifampicin-Resistant tuberculosis during pregnancy and Post-Partum: A narrative review. Pathogens. 2023;12:1385.","journal-title":"Pathogens"},{"key":"746_CR82","doi-asserted-by":"crossref","unstructured":"Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ et al. Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients. Eur Respir J. 2019;53.","DOI":"10.1183\/13993003.02107-2018"},{"key":"746_CR83","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1128\/AAC.00354-15","volume":"59","author":"S-I Park","year":"2015","unstructured":"Park S-I, Oh J, Jang K, Yoon J, Moon SJ, Park JS, et al. Pharmacokinetics of Second-Line antituberculosis drugs after multiple administrations in healthy volunteers. Antimicrob Agents Chemother. 2015;59:4429\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR84","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ijantimicag.2017.01.024","volume":"49","author":"MJ Chang","year":"2017","unstructured":"Chang MJ, Jin B, Chae J, Yun H, Kim ES, Lee YJ, et al. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and Kanamycin for the treatment of multi-drug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49:677\u201387.","journal-title":"Int J Antimicrob Agents"},{"key":"746_CR85","unstructured":"WHO. Technical report on the pharmacokinetics and pharmacodynamics (PK\/PD) of medicines used in the treatment of drug-resistant tuberculosis. Pub. World Health Organization, Geneva, Switzerland; 2018."},{"key":"746_CR86","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1128\/AAC.45.7.2160-2162.2001","volume":"45","author":"P Villani","year":"2001","unstructured":"Villani P, Viale P, Signorini L, Cadeo B, Marchetti F, Villani A, et al. Pharmacokinetic evaluation of oral Levofloxacin in human immunodeficiency Virus-Infected subjects receiving concomitant antiretroviral therapy. Antimicrob Agents Chemother. 2001;45:2160\u20132.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR87","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1111\/bcp.15380","volume":"88","author":"R Court","year":"2022","unstructured":"Court R, Gausi K, Mkhize B, Wiesner L, Waitt C, McIlleron H, et al. Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. Br J Clin Pharmacol. 2022;88:3548\u201358.","journal-title":"Br J Clin Pharmacol"},{"key":"746_CR88","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/cid\/ciad767","volume":"79","author":"T Crocker-Buque","year":"2024","unstructured":"Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, Tigay Z, et al. Pregnancy outcomes in Multidrug-Resistant tuberculosis in TB-PRACTECAL. Clin Infect Dis. 2024;79:569\u201370.","journal-title":"Clin Infect Dis"},{"key":"746_CR89","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/FTD.0000000000001164","volume":"46","author":"AK Bhatnagar","year":"2024","unstructured":"Bhatnagar AK, Hemanthkumar AK, Muthu Vijayalakshmi M, Vohra V, Padmapriyadarsini C, Ramesh PM, et al. Effect of bedaquiline and Delamanid pharmacokinetics on sputum culture conversion and adverse events in Drug-Resistant tuberculosis. Ther Drug Monit. 2024;46:363.","journal-title":"Ther Drug Monit"},{"key":"746_CR90","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/jac\/dkac067","volume":"77","author":"CM Upton","year":"2022","unstructured":"Upton CM, Steele CI, Maartens G, Diacon AH, Wiesner L, Dooley KE. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother. 2022;77:1720\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"746_CR91","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40262-022-01133-2","volume":"61","author":"L Tanneau","year":"2022","unstructured":"Tanneau L, Karlsson MO, Diacon AH, Shenje J, De Los Rios J, Wiesner L, et al. Population pharmacokinetics of Delamanid and its main metabolite DM-6705 in Drug-Resistant tuberculosis patients receiving Delamanid alone or coadministered with bedaquiline. Clin Pharmacokinet. 2022;61:1177\u201385.","journal-title":"Clin Pharmacokinet"},{"key":"746_CR92","doi-asserted-by":"crossref","unstructured":"Stancil SL, Mirzayev F, Abdel-Rahman SM. Profiling pretomanid as a therapeutic option for TB infection: evidence to date. Drug Des Devel Ther. 2021;15:2815\u201330.","DOI":"10.2147\/DDDT.S281639"},{"key":"746_CR93","doi-asserted-by":"publisher","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","volume":"51","author":"AP MacGowan","year":"2003","unstructured":"MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51:ii17\u201325.","journal-title":"J Antimicrob Chemother"},{"key":"746_CR94","doi-asserted-by":"publisher","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","volume":"66","author":"MS Dryden","year":"2011","unstructured":"Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66:iv7\u201315.","journal-title":"J Antimicrob Chemother"},{"key":"746_CR95","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1128\/AAC.01885-13","volume":"58","author":"LM Boak","year":"2014","unstructured":"Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58:2334\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR96","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-017-0601-x","volume":"57","author":"C Roger","year":"2018","unstructured":"Roger C, Roberts JA, Muller L. Clinical pharmacokinetics and pharmacodynamics of Oxazolidinones. Clin Pharmacokinet. 2018;57:559\u201375.","journal-title":"Clin Pharmacokinet"},{"key":"746_CR97","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","volume":"75","author":"MT Abdelwahab","year":"2020","unstructured":"Abdelwahab MT, Wasserman S, Brust JCM, Gandhi NR, Meintjes G, Everitt D, et al. Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother. 2020;75:3269\u201377.","journal-title":"J Antimicrob Chemother"},{"key":"746_CR98","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/jac\/dkw426","volume":"72","author":"MC Cholo","year":"2017","unstructured":"Cholo MC, Mothiba MT, Fourie B, Anderson R. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents Clofazimine and bedaquiline. J Antimicrob Chemother. 2017;72:338\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"746_CR99","doi-asserted-by":"publisher","unstructured":"Chirehwa MT, Court R, de Kock M, Wiesner L, de Vries N, Harding J, et al. Effect of Isoniazid intake on ethionamide pharmacokinetics and target attainment in Multidrug-Resistant tuberculosis patients. Antimicrob Agents Chemother. 2021;65. https:\/\/doi.org\/10.1128\/aac.00278-21.","DOI":"10.1128\/aac.00278-21"},{"key":"746_CR100","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1111\/bcp.14795","volume":"87","author":"P Mugabo","year":"2021","unstructured":"Mugabo P, Mulubwa M. Ethionamide population pharmacokinetics\/pharmacodynamics and therapeutic implications in South African adult patients with drug-resistant tuberculosis. Br J Clin Pharmacol. 2021;87:3863\u201370.","journal-title":"Br J Clin Pharmacol"},{"key":"746_CR101","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1093\/cid\/ciy624","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Alffenaar J-WC, K\u00f6ser CU, Dheda K, Chapagain ML, Simbar N, et al. d-Cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in Multidrug-resistant tuberculosis: A faustian deal. Clin Infect Dis. 2018;67:S308\u201316.","journal-title":"Clin Infect Dis"},{"key":"746_CR102","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1592\/phco.21.11.891.34524","volume":"21","author":"M Zhu","year":"2001","unstructured":"Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with High-Fat meal, orange juice, and antacids. Pharmacotherapy: J Hum Pharmacol Drug Therapy. 2001;21:891\u20137.","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"key":"746_CR103","doi-asserted-by":"publisher","unstructured":"Chirehwa MT, Court R, de Kock M, Wiesner L, de Vries N, Harding J, et al. Population pharmacokinetics of cycloserine and pharmacokinetic\/pharmacodynamic target attainment in Multidrug-Resistant tuberculosis patients dosed with terizidone. Antimicrob Agents Chemother. 2020;64. https:\/\/doi.org\/10.1128\/aac.01381-20.","DOI":"10.1128\/aac.01381-20"},{"key":"746_CR104","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5588\/ijtld.17.0475","volume":"22","author":"R Court","year":"2018","unstructured":"Court R, Wiesner L, Stewart A, de Vries N, Harding J, Maartens G, et al. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2018;22:30\u20133.","journal-title":"Int J Tuberc Lung Dis"},{"key":"746_CR105","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/bcp.13975","volume":"85","author":"M Mulubwa","year":"2019","unstructured":"Mulubwa M, Mugabo P. Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis. Br J Clin Pharmacol. 2019;85:1946\u201356.","journal-title":"Br J Clin Pharmacol"},{"key":"746_CR106","doi-asserted-by":"publisher","first-page":"114201","DOI":"10.1016\/j.ejmech.2022.114201","volume":"232","author":"PV Hegde","year":"2022","unstructured":"Hegde PV, Howe MD, Zimmerman MD, Boshoff HIM, Sharma S, Remache B, et al. Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS). Eur J Med Chem. 2022;232:114201.","journal-title":"Eur J Med Chem"},{"key":"746_CR107","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/bcp.15056","volume":"88","author":"MM Parvez","year":"2022","unstructured":"Parvez MM, Kalkisim S, Nguyen PTT, Jung JA, Park J-K, Ghim J-L, et al. Para-aminosalicylic acid significantly reduced Tenofovir exposure in human subjects: mismatched findings from in vitro to in vivo translational research. Br J Clin Pharmacol. 2022;88:1159\u201369.","journal-title":"Br J Clin Pharmacol"},{"key":"746_CR108","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1111\/bcp.14395","volume":"86","author":"AA Abulfathi","year":"2020","unstructured":"Abulfathi AA, Donald PR, Adams K, Svensson EM, Diacon AH, Reuter H. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. Br J Clin Pharmacol. 2020;86:2123\u201332.","journal-title":"Br J Clin Pharmacol"},{"key":"746_CR109","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1128\/AAC.03073-14","volume":"58","author":"L de Kock","year":"2014","unstructured":"de Kock L, Sy SKB, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, et al. Pharmacokinetics of para-Aminosalicylic acid in HIV-Uninfected and HIV-Coinfected tuberculosis patients receiving antiretroviral therapy, managed for Multidrug-Resistant and extensively Drug-Resistant tuberculosis. Antimicrob Agents Chemother. 2014;58:6242\u201350.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"746_CR110","first-page":"25","volume":"62","author":"G Momekov","year":"2015","unstructured":"Momekov G, Momekova D, Stavrakov G, Voynikov Y, Peikov P. Para-aminosalicylic acid - Biopharmaceutical, pharmacological, and clinical features and resurgence as an anti-tuberculous agent. Pharmacia. 2015;62(1):25\u201351.","journal-title":"Pharmacia"},{"key":"746_CR111","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","volume":"10","author":"C Woodward","year":"2009","unstructured":"Woodward C, Hall A, Williams I, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482\u20137.","journal-title":"HIV Med"},{"key":"746_CR112","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.1093\/cid\/ciy613","volume":"67","author":"MGG Sturkenboom","year":"2018","unstructured":"Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar J-WC. Amikacin dosing for MDR tuberculosis: A systematic review to Establish or revise the current recommended dose for tuberculosis treatment. Clin Infect Dis. 2018;67:S303\u20137.","journal-title":"Clin Infect Dis"},{"key":"746_CR113","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1128\/AAC.01050-15","volume":"59","author":"C Modongo","year":"2015","unstructured":"Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T. Amikacin concentrations predictive of ototoxicity in Multidrug-Resistant tuberculosis patients. Antimicrob Agents Chemother. 2015;59:6337\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR114","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.1093\/cid\/ciy608","volume":"67","author":"T Gumbo","year":"2018","unstructured":"Gumbo T, Alffenaar J-WC. Pharmacokinetic\/Pharmacodynamic background and methods and scientific evidence base for dosing of Second-line tuberculosis drugs. Clin Infect Dis. 2018;67:S267\u201373.","journal-title":"Clin Infect Dis"},{"key":"746_CR115","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMcp2108501","volume":"385","author":"M Shah","year":"2021","unstructured":"Shah M, Dorman SE. Latent tuberculosis infection. N Engl J Med. 2021;385:2271\u201380.","journal-title":"N Engl J Med"},{"key":"746_CR116","doi-asserted-by":"publisher","first-page":"e49928","DOI":"10.1371\/journal.pone.0049928","volume":"7","author":"AD Kerkhoff","year":"2012","unstructured":"Kerkhoff AD, Kranzer K, Samandari T, Nakiyingi-Miiro J, Whalen CC, Harries AD, et al. Systematic review of TST responses in people living with HIV in under-resourced settings: implications for Isoniazid preventive therapy. PLoS ONE. 2012;7:e49928.","journal-title":"PLoS ONE"},{"key":"746_CR117","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/QAI.0000000000000109","volume":"66","author":"JS Doyle","year":"2014","unstructured":"Doyle JS, Bissessor M, Denholm JT, Ryan N, Fairley CK, Leslie DE. Latent tuberculosis screening using interferon-gamma release assays in an Australian HIV-infected cohort: is routine testing worthwhile? J Acquir Immune Defic Syndr. 2014;66:48\u201354.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"746_CR118","doi-asserted-by":"publisher","first-page":"m549","DOI":"10.1136\/bmj.m549","volume":"368","author":"JR Campbell","year":"2020","unstructured":"Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549.","journal-title":"BMJ"},{"key":"746_CR119","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","volume":"384","author":"MX Rangaka","year":"2014","unstructured":"Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682\u201390.","journal-title":"Lancet"},{"key":"746_CR120","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"C Danel","year":"2015","unstructured":"TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and Isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808\u201322.","journal-title":"N Engl J Med"},{"key":"746_CR121","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","volume":"5","author":"A Badje","year":"2017","unstructured":"Badje A, Moh R, Gabillard D, Gu\u00e9hi C, Kabran M, Ntakp\u00e9 J-B, et al. Effect of Isoniazid preventive therapy on risk of death in West african, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5:e1080\u20139.","journal-title":"Lancet Glob Health"},{"key":"746_CR122","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2352-3018(20)30299-X","volume":"8","author":"JM Ross","year":"2021","unstructured":"Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, et al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV. 2021;8:e8\u201315.","journal-title":"Lancet HIV"},{"key":"746_CR123","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1097\/QAI.0b013e31821ac9c1","volume":"57","author":"CR Gounder","year":"2011","unstructured":"Gounder CR, Wada NI, Kensler C, Violari A, McIntyre J, Chaisson RE, et al. Active tuberculosis case-finding among pregnant women presenting to antenatal clinics in soweto, South Africa. J Acquir Immune Defic Syndr. 2011;57:e77\u201384.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"746_CR124","doi-asserted-by":"publisher","first-page":"2401108","DOI":"10.1080\/07853890.2024.2401108","volume":"56","author":"J Wen","year":"2024","unstructured":"Wen J, He J-Q. Clinical characteristics and pregnancy outcomes in pregnant women with TB: a retrospective cohort study. Ann Med. 2024;56:2401108.","journal-title":"Ann Med"},{"key":"746_CR125","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1097\/AOG.0000000000003890","volume":"135","author":"K Miele","year":"2020","unstructured":"Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. Obstet Gynecol. 2020;135:1444\u201353.","journal-title":"Obstet Gynecol"},{"key":"746_CR126","unstructured":"CDC. Tuberculosis in Pregnancy. Tuberculosis (TB) 2024. Available from: https:\/\/www.cdc.gov\/tb\/about\/pregnancy.html (accessed January 15, 2025)."},{"key":"746_CR127","unstructured":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV; 2024. Available from: clinicalinfo.hiv.gov. (accessed January 15, 2025)."},{"key":"746_CR128","unstructured":"Department of Health, Republic of South Africa. Circular revised guidance on TB preventative therapy TPT in pregnancy 30 January 2025. Pub. Department of Health, Republic of South Africa; 2025."},{"key":"746_CR129","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1093\/cid\/ciaa805","volume":"73","author":"G Theron","year":"2021","unstructured":"Theron G, Brummel S, Fairlie L, Pinilla M, McCarthy K, Owor M, et al. Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy. Clin Infect Dis. 2021;73:e312\u201320.","journal-title":"Clin Infect Dis"},{"key":"746_CR130","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/23744235.2023.2228406","volume":"55","author":"\u00c5 Arvidsson","year":"2023","unstructured":"Arvidsson \u00c5, Lafta G, S\u00f6nnerbrandt M, Sundelin K, Paues J. The cascade of care for pregnant women with latent tuberculosis infection in a high-income country. Infect Dis (Lond). 2023;55:635\u201345.","journal-title":"Infect Dis (Lond)"},{"key":"746_CR131","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1513\/AnnalsATS.201704-326OC","volume":"15","author":"RN Moro","year":"2018","unstructured":"Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, et al. Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials. Ann Am Thorac Soc. 2018;15:570\u201380.","journal-title":"Ann Am Thorac Soc"},{"key":"746_CR132","volume-title":"Recommendation on 36 months Isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings \u2013 2015 update","author":"WHO","year":"2015","unstructured":"WHO. Recommendation on 36 months Isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings \u2013 2015 update. Geneva, Switzerland: Pub. World Health Organization; 2015."},{"key":"746_CR133","doi-asserted-by":"publisher","first-page":"e784","DOI":"10.1093\/cid\/ciaa1482","volume":"72","author":"G Theron","year":"2021","unstructured":"Theron G, Montepiedra G, Aaron L, McCarthy K, Chakhtoura N, Jean-Philippe P, et al. Individual and composite adverse pregnancy outcomes in a randomized trial on Isoniazid preventative therapy among women living with human immunodeficiency virus. Clin Infect Dis. 2021;72:e784\u201390.","journal-title":"Clin Infect Dis"},{"key":"746_CR134","unstructured":"Cherkos AS, LaCourse SM, Enquobahrie DA, Richardson BA, Bradford S, Montepiedra G et al. Effect of pregnancy versus postpartum maternal Isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial. eClinicalMedicine. 2023;58."},{"key":"746_CR135","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMc1916664","volume":"382","author":"T Tiendrebeogo","year":"2020","unstructured":"Tiendrebeogo T, Anglaret X, Becquet R. HIV, pregnancy, and Isoniazid preventive therapy. N Engl J Med. 2020;382:1184.","journal-title":"N Engl J Med"},{"key":"746_CR136","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.reprotox.2018.07.062","volume":"80","author":"EK Kalk","year":"2018","unstructured":"Kalk EK, Heekes A, Mehta U, De Waal R, Jacob N, Cohen K, et al. Programmatic review of safety and effectiveness of Isoniazid preventive therapy in HIV-infected pregnant women on ART in routine care. Reprod Toxicol. 2018;80:155.","journal-title":"Reprod Toxicol"},{"key":"746_CR137","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/cid\/ciad583","volume":"78","author":"A Gupta","year":"2024","unstructured":"Gupta A, Hughes MD, Cruz JL, Avihingsanon A, Mwelase N, Severe P, et al. Adverse pregnancy outcomes among women with human immunodeficiency virus taking Isoniazid preventive therapy during the first trimester. Clin Infect Dis. 2024;78:667\u201373.","journal-title":"Clin Infect Dis"},{"key":"746_CR138","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus Isoniazid to prevent HIV-Related tuberculosis. N Engl J Med. 2019;380:1001\u201311.","journal-title":"N Engl J Med"},{"key":"746_CR139","doi-asserted-by":"publisher","first-page":"195637","DOI":"10.1155\/2013\/195637","volume":"2013","author":"AW Taylor","year":"2013","unstructured":"Taylor AW, Mosimaneotsile B, Mathebula U, Mathoma A, Moathlodi R, Theebetsile I, et al. Pregnancy outcomes in HIV-infected women receiving long-term Isoniazid prophylaxis for tuberculosis and antiretroviral therapy. Infect Dis Obstet Gynecol. 2013;2013:195637.","journal-title":"Infect Dis Obstet Gynecol"},{"key":"746_CR140","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","volume":"7","author":"KE Dooley","year":"2020","unstructured":"Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, et al. Once-weekly rifapentine and Isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial. Lancet HIV. 2020;7:e401\u20139.","journal-title":"Lancet HIV"},{"key":"746_CR141","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Considerations for antiretroviral use in people with coinfection: hepatitis B virus\/HIV coinfection. 2024 Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/panel-roster (accessed January 15, 2025)."},{"key":"746_CR142","doi-asserted-by":"publisher","first-page":"e0296993","DOI":"10.1371\/journal.pone.0296993","volume":"19","author":"Y Hirsch-Moverman","year":"2024","unstructured":"Hirsch-Moverman Y, Hsu A, Abrams EJ, Killam WP, Moore B, Howard AA. Guidelines for tuberculosis screening and preventive treatment among pregnant and breastfeeding women living with HIV in PEPFAR-supported countries. PLoS ONE. 2024;19:e0296993.","journal-title":"PLoS ONE"},{"key":"746_CR143","volume-title":"WHO operational handbook on tuberculosis. Module 4 treatment - Drug-Susceptible tuberculosis.Treatment","author":"World Health Organisation","year":"2021","unstructured":"World Health Organisation. WHO operational handbook on tuberculosis. Module 4 treatment - Drug-Susceptible tuberculosis.Treatment. Pub: World Health Organization, Geneva, Switzerland;; 2021."},{"key":"746_CR144","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of Drug-Susceptible tuberculosis. Clin Infect Dis. 2016;63:e147\u201395.","journal-title":"Clin Infect Dis"},{"key":"746_CR145","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/1471-0528.16573","volume":"128","author":"K Alene","year":"2021","unstructured":"Alene K, Jegnie A, Adane A. Multidrug-resistant tuberculosis during pregnancy and adverse birth outcomes: a systematic review and meta\u2010analysis. BJOG. 2021;128:1125\u201333.","journal-title":"BJOG"},{"key":"746_CR146","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/jac\/dkab505","volume":"77","author":"SE Mudde","year":"2022","unstructured":"Mudde SE, Upton AM, Lenaerts A, Bax HI, De Steenwinkel JEM. Delamanid or pretomanid? A Solomonic judgement! J Antimicrob Chemother. 2022;77:880\u2013902.","journal-title":"J Antimicrob Chemother"},{"key":"746_CR147","doi-asserted-by":"crossref","unstructured":"Fong IW. Chapter 9 - New Anti-tuberculous drugs: bedaquiline, delamanid, and pretomanid. In: Fong IW, editor. New antimicrobials: for the present and the future, pub. Springer International Publishing; 2023. p. 115\u201327.","DOI":"10.1007\/978-3-031-26078-0_9"},{"key":"746_CR148","volume-title":"WHO operational handbook on tuberculosis: module 4: treatment Drug-resistant tuberculosis treatment 2022 update","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO operational handbook on tuberculosis: module 4: treatment Drug-resistant tuberculosis treatment 2022 update. Geneva, Switzerland: Pub. World Health Organization; 2022."},{"key":"746_CR149","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline\u2013Pretomanid\u2013Linezolid regimens for Drug-Resistant tuberculosis. N Engl J Med. 2022;387:810\u201323.","journal-title":"N Engl J Med"},{"key":"746_CR150","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"B-T Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral regimen for Rifampin-Resistant tuberculosis. N Engl J Med. 2022;387:2331\u201343.","journal-title":"N Engl J Med"},{"key":"746_CR151","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"B-T Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respiratory Med. 2024;12:117\u201328.","journal-title":"Lancet Respiratory Med"},{"key":"746_CR152","doi-asserted-by":"publisher","first-page":"e2216527","DOI":"10.1001\/jamanetworkopen.2022.16527","volume":"5","author":"KA Alene","year":"2022","unstructured":"Alene KA, Murray MB, van de Water BJ, Becerra MC, Atalell KA, Nicol MP, et al. Treatment outcomes among pregnant patients with Multidrug-Resistant tuberculosis: A systematic review and Meta-analysis. JAMA Netw Open. 2022;5:e2216527.","journal-title":"JAMA Netw Open"},{"key":"746_CR153","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/cid\/ciad445","volume":"78","author":"I Lotia Farrukh","year":"2024","unstructured":"Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed S, Algozhin Y, Coutisson S, et al. Pregnancy and birth outcomes in patients with Multidrug-Resistant tuberculosis treated with regimens that include new and repurposed drugs. Clin Infect Dis. 2024;78:144\u20138.","journal-title":"Clin Infect Dis"},{"key":"746_CR154","volume-title":"Management of Drug-Resistant tuberculosis in pregnant and peripartum people: a field guide","author":"The Sentinel Project for Pediatric Drug-Resistant Tuberculosis","year":"2022","unstructured":"The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant tuberculosis in pregnant and peripartum people: a field guide. Pub: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis, Boston, USA;; 2022."},{"key":"746_CR155","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","author":"WHO","year":"2021","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Pub: World Health Organization, Geneva, Switzerland;; 2021."},{"key":"746_CR156","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/QAI.0b013e3182410503","volume":"59","author":"KE Dooley","year":"2012","unstructured":"Dooley KE, Park J-G, Swindells S, Allen R, Haas DW, Cramer Y, et al. Safety, tolerability, and Pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with Efavirenz in healthy volunteers: AIDS clinical trials group study A5267. J Acquir Immune Defic Syndr. 2012;59:455\u201362.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"746_CR157","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1128\/AAC.00191-13","volume":"57","author":"EM Svensson","year":"2013","unstructured":"Svensson EM, Aweeka F, Park J-G, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of Efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57:2780\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR158","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1128\/AAC.03332-14","volume":"58","author":"KE Dooley","year":"2014","unstructured":"Dooley KE, Luetkemeyer AF, Park J-G, Allen R, Cramer Y, Murray S, et al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or Rifampin. Antimicrob Agents Chemother. 2014;58:5245\u201352.","journal-title":"Antimicrob Agents Chemother"},{"key":"746_CR159","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/jac\/dkv447","volume":"71","author":"M Pandie","year":"2016","unstructured":"Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir\/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016;71:1037\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"746_CR160","doi-asserted-by":"publisher","first-page":"784","DOI":"10.5588\/ijtld.21.0327","volume":"25","author":"S Horter","year":"2021","unstructured":"Horter S, Daftary A, Keam T, Bernays S, Bhanushali K, Chavan D, et al. Person-centred care in TB. Int J Tuberc Lung Dis. 2021;25:784\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"746_CR161","doi-asserted-by":"publisher","first-page":"e0155147","DOI":"10.1371\/journal.pone.0155147","volume":"11","author":"HH Tola","year":"2016","unstructured":"Tola HH, Shojaeizadeh D, Tol A, Garmaroudi G, Yekaninejad MS, Kebede A, et al. Psychological and educational intervention to improve tuberculosis treatment adherence in Ethiopia based on health belief model: A cluster randomized control trial. PLoS ONE. 2016;11:e0155147.","journal-title":"PLoS ONE"},{"key":"746_CR162","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1037\/hea0000606","volume":"37","author":"CR Rooks-Peck","year":"2018","unstructured":"Rooks-Peck CR, Adegbite AH, Wichser ME, Ramshaw R, Mullins MM, Higa D, et al. Mental health and retention in HIV care: A systematic review and meta-analysis. Health Psychol. 2018;37:574\u201385.","journal-title":"Health Psychol"},{"key":"746_CR163","volume-title":"WHO guideline on health policy and system support to optimize community health worker programmes","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. WHO guideline on health policy and system support to optimize community health worker programmes. Pub: World Health Organization, Geneva, Switzerland;; 2018."},{"key":"746_CR164","doi-asserted-by":"publisher","first-page":"iv27","DOI":"10.1093\/heapol\/czw169","volume":"32","author":"FLH Chuah","year":"2017","unstructured":"Chuah FLH, Haldane VE, Cervero-Liceras F, Ong SE, Sigfrid LA, Murphy G, et al. Interventions and approaches to integrating HIV and mental health services: a systematic review. Health Policy Plan. 2017;32:iv27\u201347.","journal-title":"Health Policy Plan"},{"key":"746_CR165","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1365-3156.2012.02958.x","volume":"17","author":"L Ferguson","year":"2012","unstructured":"Ferguson L, Grant AD, Watson-Jones D, Kahawita T, Ong\u2019ech JO, Ross DA. Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review. Trop Med Int Health. 2012;17:564\u201380.","journal-title":"Trop Med Int Health"},{"key":"746_CR166","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1086\/521250","volume":"45","author":"ML Petersen","year":"2007","unstructured":"Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007;45:908\u201315.","journal-title":"Clin Infect Dis"},{"key":"746_CR167","doi-asserted-by":"crossref","unstructured":"Fielding KL, Subbaraman R, Khan A, Celan C, Charalambous S, Franke MF, et al. The use of digital technologies in adherence to anti-tuberculosis treatment. In: Pinnock H, Poberezhets V, Drummond D, editors. Digital Respiratory Healthcare. Sheffield: European Respiratory Society; 2023.","DOI":"10.1183\/2312508X.10002223"},{"key":"746_CR168","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/s12913-023-09737-5","volume":"23","author":"G Sarwar","year":"2023","unstructured":"Sarwar G, Khan SM, Irfan SD, Khan MNM, Reza MM, Rana AKMM, et al. Community based peer-led TB screening intervention: an innovative approach to increase TB knowledge, presumptive case identification, and referral among sexual minority people in urban Bangladesh. BMC Health Serv Res. 2023;23:810.","journal-title":"BMC Health Serv Res"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00746-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00746-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00746-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:04:25Z","timestamp":1769609065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00746-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":168,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00746-z","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"28 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a review of published data no ethical approval was sought or is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"37"}}